Bio-Path Holdings Past Earnings Performance
Past criteria checks 0/6
Bio-Path Holdings's earnings have been declining at an average annual rate of -10.2%, while the Biotechs industry saw earnings growing at 19.3% annually.
Key information
-10.2%
Earnings growth rate
23.1%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
We're Keeping An Eye On Bio-Path Holdings' (NASDAQ:BPTH) Cash Burn Rate
Nov 05
Bio-Path GAAP EPS of -$0.42 beats by $0.07
Aug 16Is Bio-Path Holdings (NASDAQ:BPTH) In A Good Position To Deliver On Growth Plans?
Jul 08Here's Why We're Not Too Worried About Bio-Path Holdings' (NASDAQ:BPTH) Cash Burn Situation
Mar 24Bio-Path Holdings (NASDAQ:BPTH) Is In A Good Position To Deliver On Growth Plans
Aug 17We Think Bio-Path Holdings (NASDAQ:BPTH) Needs To Drive Business Growth Carefully
Mar 26Will Bio-Path Holdings (NASDAQ:BPTH) Spend Its Cash Wisely?
Dec 11Dosing underway in Bio-Path's early-stage BP1002 study
Nov 19Bio-Path EPS beats by $0.07
Nov 13Revenue & Expenses Breakdown
How Bio-Path Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -11 | 5 | 8 |
| 30 Jun 24 | 0 | -12 | 4 | 9 |
| 31 Mar 24 | 0 | -14 | 4 | 10 |
| 31 Dec 23 | 0 | -16 | 4 | 12 |
| 30 Sep 23 | 0 | -17 | 5 | 12 |
| 30 Jun 23 | 0 | -17 | 5 | 12 |
| 31 Mar 23 | 0 | -16 | 5 | 11 |
| 31 Dec 22 | 0 | -14 | 5 | 9 |
| 30 Sep 22 | 0 | -14 | 5 | 9 |
| 30 Jun 22 | 0 | -13 | 5 | 8 |
| 31 Mar 22 | 0 | -11 | 5 | 7 |
| 31 Dec 21 | 0 | -10 | 5 | 6 |
| 30 Sep 21 | 0 | -9 | 4 | 5 |
| 30 Jun 21 | 0 | -10 | 4 | 6 |
| 31 Mar 21 | 0 | -10 | 4 | 6 |
| 31 Dec 20 | 0 | -11 | 4 | 7 |
| 30 Sep 20 | 0 | -11 | 4 | 6 |
| 30 Jun 20 | 0 | -10 | 4 | 6 |
| 31 Mar 20 | 0 | -10 | 4 | 6 |
| 31 Dec 19 | 0 | -9 | 4 | 5 |
| 30 Sep 19 | 0 | -8 | 4 | 4 |
| 30 Jun 19 | 0 | -9 | 4 | 5 |
| 31 Mar 19 | 0 | -8 | 4 | 4 |
| 31 Dec 18 | 0 | -9 | 3 | 5 |
| 30 Sep 18 | 0 | -9 | 3 | 5 |
| 30 Jun 18 | 0 | -8 | 4 | 5 |
| 31 Mar 18 | 0 | -10 | 4 | 5 |
| 31 Dec 17 | 0 | -8 | 4 | 5 |
| 30 Sep 17 | 0 | -7 | 3 | 5 |
| 30 Jun 17 | 0 | -6 | 3 | 6 |
| 31 Mar 17 | 0 | -5 | 3 | 5 |
| 31 Dec 16 | 0 | -7 | 3 | 5 |
| 30 Sep 16 | 0 | -7 | 3 | 5 |
| 30 Jun 16 | 0 | -7 | 3 | 4 |
| 31 Mar 16 | 0 | -6 | 3 | 3 |
| 31 Dec 15 | 0 | -5 | 2 | 3 |
| 30 Sep 15 | 0 | -6 | 3 | 3 |
| 30 Jun 15 | 0 | -5 | 3 | 2 |
| 31 Mar 15 | 0 | -5 | 3 | 2 |
| 31 Dec 14 | 0 | -5 | 3 | 2 |
| 30 Sep 14 | 0 | -4 | 2 | 2 |
| 30 Jun 14 | 0 | -4 | 2 | 2 |
| 31 Mar 14 | 0 | -3 | 2 | 1 |
Quality Earnings: BPTH is currently unprofitable.
Growing Profit Margin: BPTH is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BPTH is unprofitable, and losses have increased over the past 5 years at a rate of 10.2% per year.
Accelerating Growth: Unable to compare BPTH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BPTH is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: BPTH's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.